Boyds is a global drug development consultancy helping to translate ideas into cutting-edge medicinal products and treatments for the benefit of patients.

Founded in 2005 by Professor Alan Boyd, we work with pharma companies, biotechs, spin-outs, medical device companies and academic institutions, providing expert support at any stage of their drug development journey, across a range of therapeutic areas.

The Boyds’ team are all industry experts with the breadth and depth of experience central to the development of pharmaceutical and biotechnology medicinal products and medical devices. We specialise in ATMPs, cell and gene therapies and orphan drugs, focusing on cutting-edge medicinal products and treatments.

We provide clients with support in programme management and product development, clinical operations, medical monitoring, regulatory affairs and strategy, medical writing and scientific and medical advice to help translate ideas into medicines.

Our team has the expertise needed to help clients navigate the whole pathway from concept to bench to patient. Alongside our expertise is our reputation with the regulatory bodies, key opinion leaders and other professionals in the industry as well as our network of specialists, which makes us an ideal partner for clients looking for support at any part of the process.

Our geographic spread, with offices in the UK, EU and US, makes it easier for clients trying to achieve global development and approval of their products. We understand that no two projects (or products) are the same which is why we work with our clients as part of their team to offer a bespoke and tailored service that will help achieve project milestones and get the product approved and onto the market – whilst navigating and overcoming the inevitable hurdles along the way.

We enjoy thinking outside the box and supporting the development of novel, emerging and cutting-edge technologies.